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Maternal Medicine, University of Glasgow, Glasgow, United KingdomObjective: To assess the relationships between serum antim€ullerian hormone (AMH) and ovarian response and treatment outcomes in good-
prognosis patients undergoing controlled ovarian stimulation using a gonadotropin-releasing hormone (GnRH) antagonist protocol.
Design: Secondary analysis of data prospectively collected in a randomized, assessor-blind trial comparing two different gonadotropin
preparations with respect to ongoing pregnancy rate.
Setting: Twenty-ﬁve centers in seven countries.
Patient(s): 749 women, aged 21 to 34 years, with primary diagnosis of infertility being unexplained infertility or mild male factor infertility and
with serum follicle-stimulating hormone (FSH) level 1–12 IU/L and antral follicle count (AFC)R10.
Intervention(s): Controlled ovarian stimulation with highly puriﬁed human menopausal gonadotropin (hphMG) or recombinant FSH in a GnRH
antagonist cycle with compulsory single-blastocyst transfer and potential subsequent 1-year cryopreserved blastocyst replacement in natural cycles.
Main Outcome Measure(s): Relationships between AMH at start of stimulation and ovarian response and treatment outcome.
Result(s): Serum AMH concentration was strongly correlated with oocyte yield: AMH accounted for 85%, FSH for 14%, and inhibin B and AFC for
<1% each of the explained variation in oocyte yield. Also, AMH showed a high accuracy for the prediction of poor (%3 oocytes) and high response
(R15 oocytes), which was statistically signiﬁcantly better than basal FSH, AFC, or inhibin B. AMHwas statistically signiﬁcantly positively associated
with ongoing pregnancy rate in the fresh cycle as well as with the 1-year cumulative ongoing pregnancy and live-birth rates.
Conclusion(s): There is a positive relationship between AMH and oocyte yield in GnRH antagonist cycles, and AMH is the best predictor for iden-Use your smartphonetifying patients with poor and high ovarian response. The positive association between AMH and cumu-
lative live-birth rates after fresh and cryopreserved cycles reﬂects the availability of more oocytes/
blastocysts, not higher quality.
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Fertility and Sterility®T he circulating concentration of antim€ullerian hormone(AMH) has been demonstrated to be a reliable surrogatemarker for the functional ovarian follicle reserve (1, 2).
In assisted reproductive technology (ART), serum AMH has
been shown to be a better endocrine indicator of a patient's
follicular response to controlled ovarian stimulation (COS)
with gonadotropins than the basal levels of follicle-
stimulating hormone (FSH), estradiol, inhibin B, or the wom-
an's age (3–8). Also, AMH has been claimed to possess at least
the same level of accuracy as the antral follicle count (AFC)
for the prediction of poor (9) and excessive (10) response. In
addition, a high serum concentration of AMH before the
start of COS has been shown to be associated with increased
risk of developing ovarian hyperstimulation syndrome
(OHSS) (6, 11, 12). As with other ovarian reserve tests, AMH
has not proven to be a good predictor of embryo quality or
pregnancy in COS cycles, suggesting that AMH is a marker
of quantitative rather than qualitative aspects of the
ovarian reserve (2, 3, 10, 12, 13).
The value of serum AMH in predicting ovarian response
to COS and cycle outcome has, however, overwhelmingly
been studied in patients down-regulated with a gonadotro-
pin-releasing hormone (GnRH) agonist in a long protocol.
Only a few studies have speciﬁcally addressed the value of
AMH measurements in GnRH antagonist cycles (14–16),
and few published reports address the association between
the basal serum AMH level and ovarian response, embryo
quality, or pregnancy/live-birth rates in GnRH antagonist
regimens. It remains to be conﬁrmed that AMH is an impor-
tant predictive marker of response to COS in a manner similar
to that of a GnRH agonist protocol in patients treated with
a GnRH antagonist.
Recently, it was demonstrated that the nature of the rela-
tionship between AMH and oocyte retrieval below or above
the stimulation target differed when using different types of
gonadotropin preparations—that is, recombinant FSH or
highly puriﬁed human menopausal gonadotropin (hphMG,
menotropin)—in the long GnRH agonist protocol (3). Hence,
the type of gonadotropin preparation should be taken into
consideration when evaluating the predictive value of AMH
in GnRH antagonist cycles.
We evaluated the relationship between serum AMH and
ovarian response and treatment outcome in patients undergo-
ing COS with either hphMG or recombinant FSH using
a GnRH antagonist protocol. The results were compared
with those of other markers of ovarian reserve.MATERIALS AND METHODS
This study is a secondary analysis of data prospectively
collected in a randomized, open-label, assessor-blind,
parallel-groups, multicenter trial. The trial compared ongo-
ing pregnancy rates in patients undergoing in vitro fertiliza-
tion (IVF) after stimulation with hphMG (Menopur; Ferring
Pharmaceuticals) or recombinant FSH (follitropin beta, Pure-
gon; MSD) following a GnRH antagonist protocol after col-
lection of evidence of functional ovarian reserve. The trial
was performed in accordance with the declaration of Hel-
sinki, the International Conference on Harmonization Guide-VOL. 99 NO. 6 / MAY 2013lines for Good Clinical Practice, and local regulatory
requirements. The trial protocol was approved by both the lo-
cal regulatory authorities and the independent ethics com-
mittees covering all participating centers. Written informed
consent was provided by all patients before any trial-
related examinations were initiated. The trial design, popula-
tion, methods, conduct, and results were described previously
elsewhere (17).Trial Population
Eligible patients were women between the ages of 21 and 34
years, and the primary diagnosis for treatment of unexplained
infertility or mild male factor infertility. Further inclusion cri-
teria were serum FSH concentration between 1 and 12 IU/L
and AFC R10 measured within the last 12 months, a body
mass index (BMI) of 18 to 25 kg/m2, and regular menstrual
cycles of 24 to 35 days. Women with polycystic ovaries, en-
dometriosis stages I to IV, or poor response in a previous cycle
were excluded.Treatment Regimen
The starting gonadotropin dosage was ﬁxed at 150 IU for the
ﬁrst 5 days and adjusted according to ovarian response from
day 6 when the GnRH antagonist (ganirelix acetate, Orgalu-
tran; MSD) was initiated at a daily dose of 0.25 mg and con-
tinued throughout the gonadotropin treatment period. A
single injection of 250 mg of human chorionic gonadotropin
(hCG, choriogonadotropin alpha, Ovitrelle; Merck Serono)
was administered when three follicles of R17 mm were ob-
served. Oocyte retrieval took place 36  2 hours after the
hCG administration. All oocytes retrieved were fertilized by
intracytoplasmic sperm injection (ICSI). Fertilization was as-
sessed 19  1 hours after insemination, and embryos with
two pronuclei were cultured individually.
On day 5 (120  2 hours) after insemination, the blasto-
cyst quality was assessed using the grading system of Gardner
and Schoolcraft (18), and a single blastocyst of the best
quality was transferred. Remaining blastocysts were cryopre-
served individually by vitriﬁcation. A serum b-hCG test was
performed 13 to 15 days after blastocyst transfer. Clinical
and ongoing pregnancy was conﬁrmed by transvaginal ultra-
sound at 5 to 6 and 10 to 11 weeks, respectively, after transfer.
A patient with no ongoing pregnancy at the end of the stim-
ulated cycle/trial period and with surplus cryopreserved blas-
tocysts could undergo cryopreserved replacement cycles
within 1 year of the patient's start of treatment, with compul-
sory single-blastocyst transfer in a natural cycle on day 7
after the luteinizing hormone (LH) peak. All patients with
an established ongoing pregnancy in a fresh or cryopreserved
cycle were observed until delivery.Endocrine Assays and Antral Follicle Count
Circulating concentrations of AMH, inhibin B, FSH, LH,
estradiol, and progesterone were analyzed in the serum sam-
ples collected on stimulation day 1 before the start of stimu-
lation. The serum samples were analyzed at a central
laboratory (Laboratory for Clinical Research, Kiel, Germany).1645
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONConcentrations of AMH (1 ng/mL ¼ 7.14 pmol/L; Gen 2
ELISA; ref. no. A79765; Beckmann-Coulter) and inhibin B
were analyzed by an enzyme-linked immunosorbent assay
(ELISA). Levels of FSH, LH, estradiol, and progesterone were
analyzed by an electrochemiluminescence immunoassay
(ECLIA; Roche Diagnostics). The assays used for AMH, inhibin
B, FSH, LH, estradiol, and progesterone had a sensitivity of
0.57 pmol/L, 2.6 ng/L, 0.10 IU/L, 0.10 IU/L, 18.4 pmol/L,
0.095 nmol/L, respectively, and an intra-assay and interassay
imprecision (% coefﬁcient of variation) of 5.7 and 4.6, 10.8
and 11.4, 2.0 and 3.8, 2.1 and 1.6, 2.9 and 5.6, and 5.9 and
7.2, respectively. The AFC was deﬁned as the total number
of follicles in both ovaries on stimulation day 1 before the
start of stimulation (days 2 to 3 of the natural cycle) with a di-
ameter between 2 and 10 mm as measured by transvaginal ul-
trasound by local clinic sonographers.Statistical Analysis
All analyses were based on the intention-to-treat population.
Continuous data are presented as median and interquartile
range (IQR), and categorical data are presented as frequencies
and percentages. The ovarian response categories were
deﬁned according to the number of oocytes retrieved: poor
(%3 or cancellation due to poor response), low (4–7),
appropriate (8–14), high (15–19), and excessive response
(R20 or cancellation due to excessive response). The
correlations between baseline variables and oocytes
retrieved were evaluated using Spearman's rank correlation
coefﬁcient. Subjects were grouped according to AMH
quartiles and selected variables of interest summarized within
each quartile, overall and by treatment group. Differences
between AMH quartiles were evaluated overall using the
nonparametric Kruskal-Wallis test for continuous data, and
categorical data were evaluated using the chi-square test or
Fisher's exact test.
A regression modeling approach using log-AMH as co-
variate and treatment as factor was used to test for linear
trend and differences between treatment groups. Continuous
data were analyzed using general linear models in which the
endocrine parameters were log-transformed. Categorical
data were analyzed using generalized linear models with
canonical link functions as follows: binary data (logistic re-
gression models); ordinal data (proportional odd models);
count data (Poisson models allowing for overdispersion);
and fractions (binomial regression models allowing for
overdispersion).
The ability of selected baseline characteristics to predict
poor or high response was evaluated using receiver operating
characteristic (ROC) curves. The area under the curve (AUC)
was compared using the method described by DeLong et al.
(19). Optimal cutoff points were determined by the combina-
tion of speciﬁcity and sensitivity closest to the optimal.
RESULTS
The study included 749 women, and the primary treatment di-
agnosis was mild male factor infertility (61%) or unexplained
infertility (39%), as reported in Devroey et al. (17). The hphMG
(n ¼ 374) and recombinant FSH (n ¼ 375) treatment groups1646were similar with respect to demographics, baseline charac-
teristics, and serum hormone concentrations at start of stim-
ulation (Supplemental Table 1, available online).Markers of Baseline Ovarian Reserve
In this study population of young women (median [interquar-
tile range]: 31 [29, 32] years), a small (r ¼ 0.20) but statis-
tically signiﬁcant (P< .001) inverse correlation was
observed between age and AMH at start of stimulation
(Table 1). The serum AMH concentration before stimulation
correlated moderately with AFC (r¼ 0.48), and the correlation
coefﬁcients between AMH and serum concentrations of FSH
and inhibin B at start of stimulation were relatively lower
(r ¼ 0.32 and r ¼ 0.20, respectively). Also, AFC was weakly
correlated with FSH (r ¼ 0.19) (see Table 1).
Oocyte retrieval was performed for 97% of the patients in
each treatment group. The median number [and interquartile
range] of oocytes retrieved was statistically signiﬁcantly
(P< .001) higher in the recombinant FSH group compared
with the hphMG group: 9 [6, 14] versus 8 [5, 12]. For both
groups, AMH was more strongly correlated with the oocyte
yield than were FSH, AFC, and inhibin B (hphMG: r ¼ 0.52,
0.36, 0.33, and 0.17, respectively; recombinant FSH: r ¼
0.59, 0.38, 0.35, and 0.12, respectively) (see Table 1). Also,
AMH displayed a higher potential for distinguishing between
different ovarian response categories when compared with
FSH and inhibin B (Fig. 1). A multiple regression model re-
vealed that AMH (P< .001) and FSH (P< .001) were statisti-
cally signiﬁcant predictors of the number of oocytes
retrieved, but AFC (P¼ .125) and inhibin B (P¼ .706) were
not. In this combined model, AMH accounted for 85%, FSH
for 14%, and inhibin B and AFC for <1% each of the ex-
plained variation in oocyte yield.
We performed ROC curve analyses to assess the predic-
tive values of AMH, FSH, inhibin B, and AFC for the esti-
mation of ovarian response (Fig. 2). For both treatment
groups, AMH showed a high accuracy for the prediction
of poor and high response: hphMG, AUC ¼ 0.779 (95%
conﬁdence interval [CI], 0.742–0.816 and 0.765 (95% CI,
0.738–0.791); and recombinant FSH, AUC ¼ 0.897 (95%
CI, 0.861–0.935) and 0.813 (95% CI, 0.787–0.839). The
AMH cutoff values for prediction of poor response were
13 pmol/L (sensitivity 66%, speciﬁcity 80%) for hphMG
stimulation, and 12 pmol/L (sensitivity 92%, speciﬁcity
83%) for recombinant FSH stimulation. The AMH cutoff
values for prediction of high response were 28 pmol/L (sen-
sitivity 78%, speciﬁcity 67%) for hphMG stimulation and
31 pmol/L (sensitivity 76%, speciﬁcity 74%) for recombi-
nant FSH stimulation.
Compared with AMH, the AUC values of AFC and inhibin
B for prediction of poor as well as high response were statis-
tically signiﬁcantly (P< .001) lower in both treatment groups.
The AUC values of FSH for prediction of poor and high re-
sponse were also statistically signiﬁcantly lower compared
with those of AMH (P¼ .012 and .009, respectively). When in-
cluding both AMH and FSH for prediction of poor or high re-
sponse, the AUC values were not statistically signiﬁcantly
higher compared with those obtained with AMH only: poorVOL. 99 NO. 6 / MAY 2013
TABLE 1
Correlations between markers of ovarian reserve and ovarian response.
Age AMHa FSHa Inhibin Ba AFCa
AMH
All 0.20 (0.27, 0.13)
hphMG 0.14 (0.24, 0.04)
rFSH 0.26 (0.35, 0.16)
FSH
All 0.10 (0.03, 0.18) 0.32 (0.39, 0.26)b
hphMG 0.05 (0.05, 0.15) 0.32 (0.41, 0.23)b
rFSH 0.16 (0.05, 0.25) 0.32 (0.41, 0.23)b
Inhibin B
All 0.01 (0.06, 0.08) 0.20 (0.13, 0.27) 0.10 (0.17, 0.03)
hphMG 0.04 (0.06, 0.14) 0.27 (0.17, 0.36) 0.17 (0.26, 0.07)
rFSH 0.02 (0.12, 0.08) 0.14 (0.04, 0.24) 0.04 (0.14, 0.06)
AFC
All 0.20 (0.27, 0.13) 0.48 (0.42, 0.53)b 0.19 (0.26, 0.12) 0.09 (0.02, 0.17)
hphMG 0.17 (0.26, 0.07) 0.47 (0.39, 0.55)b 0.19 (0.29, 0.10) 0.16 (0.06, 0.26)
rFSH 0.24 (0.33, 0.14) 0.49 (0.41, 0.56)b 0.18 (0.28, 0.08) 0.03 (0.07, 0.13)
Oocytes retrieved
All 0.17 (0.24, 0.10) 0.55 (0.50, 0.60)b 0.37 (0.43, 0.31)b 0.14 (0.07, 0.21) 0.34 (0.27, 0.40)b
hphMG 0.10 (0.20, 0.01) 0.52 (0.44, 0.59)b 0.36 (0.44, 0.26)b 0.17 (0.07, 0.27) 0.33 (0.24, 0.42)b
rFSH 0.22 (0.31, 0.12) 0.59 (0.52, 0.65)b 0.38 (0.47, 0.29)b 0.12 (0.01, 0.22) 0.35 (0.26, 0.44)b
Note: Numbers are Spearman's rank correlation coefﬁcient, r (95% conﬁdence interval). AFC ¼ antral follicle count; AMH ¼ antim€ullerian hormone; FSH ¼ follicle-stimulating hormone; rFSH ¼
recombinant follicle-stimulating hormone; hphMG ¼ highly puriﬁed human menopausal gonadotropin; OHSS ¼ ovarian hyperstimulation syndrome.
a Stimulation day 1 (cycle day 2–3).
b r > 0.30 (or r < 0.30) and P< .001.
Arce. AMH, oocytes, and cumulative live births. Fertil Steril 2013.
Fertility and Sterility®response 0.820 (95% CI, 0.766–0.874) versus 0.818 (95% CI,
0.762–0.874), P¼ .774; and excessive response 0.815 (95%
CI, 0.781–0.848) versus 0.792 (95% CI, 0.756–0.828), P¼ .081.Baseline Characteristics, Stimulation
Characteristics, and Ovarian Response According
to AMH Quartiles
The patient population was stratiﬁed according to the 25th,
50th, and 75th percentiles of the serum AMH concentration
at start of stimulation. Statistically signiﬁcant differences
among the AMH quartiles were noticed for most of the
baseline and stimulation characteristics, ovarian response
variables, and the blastocyst quality for the overall study pop-
ulation and for each treatment group (Table 2).
In the group consisting of all patients with AMH <25th
percentile, a large proportion (44%) had a gonadotropin-
dose increase on stimulation day 6; despite this, cycle cancel-
lation due to poor response occurred most frequently (6%) in
this quartile. In the twomiddle quartiles (25th–50th and 50th–
75th percentiles), the majority (75%) of patients maintained
the initial dose on day 6 of stimulation, and less than 1% of
the cycles were canceled due to poor response. In the AMH
>75th percentile, interventions due to excessive ovarian re-
sponse and early moderate/severe OHSS occurred at the high-
est frequency: 10% and 4%, respectively. The median number
of oocytes retrieved statistically signiﬁcantly increased
(P< .001) across the AMH quartiles, from 5 [4, 7] in the
<25th percentile to 12 [9, 17] oocytes in the>75th percentile.
Both the proportion of patients with blastocysts available for
transfer in the fresh cycle (from 71% to 86%; P< .001) and the
number of blastocysts (from 1 [0, 2] to 3 [1, 6]; P< .001) sta-VOL. 99 NO. 6 / MAY 2013tistically signiﬁcantly increased across the AMH quartiles, but
there was no difference between the quartiles in the number of
blastocysts available for transfer when adjusting for the
number of oocytes retrieved (P¼ .937). The total number of
cryopreserved blastocysts (P< .001) and number of cryopre-
served blastocysts per oocyte retrieved (P¼ .004) as well as
the proportion of patients with cryopreserved blastocysts
available for transfer in a subsequent cycle (P< .001) statisti-
cally signiﬁcantly increased across the AMH quartiles. In re-
lation to AMH, statistically signiﬁcant differences were
observed between the hphMG and recombinant FSH groups
for several stimulation characteristics and ovarian response
variables, as detailed in Table 2.Outcome According to AMH Concentrations/
Categories
The ROC analyses indicated that AMH was not an absolute
predictor of ongoing pregnancy in the fresh cycle with either
gonadotropin (hphMG: AUC ¼ 0.573 [95% CI, 0.542–0.604];
recombinant FSH: AUC ¼ 0.476 [95% CI, 0.445–0.507). Nev-
ertheless, taking the whole patient population, a statistically
signiﬁcant (P¼ .038) association between the AMH concen-
tration and the ongoing pregnancy rate in the fresh cycle
was recorded, and a similar trend, although borderline statis-
tically signiﬁcant (P¼ .085), was also noted for the relation
between AMH and live-birth rate in the fresh cycle (see
Table 2). When comparing patients with AMH above and be-
low the 50th percentile, both the ongoing pregnancy rate
(32% vs. 23%, P¼ .006) and live-birth rate (31% vs. 23%,
P¼ .022) in the fresh cycle were statistically signiﬁcantly in-
creased in patients with high AMH levels. Also, statistically1647
FIGURE 1
Box and whisker plots for antim€ullerian hormone (AMH), follicle-stimulating hormone (FSH), inhibin B, and antral follicle count (AFC) at start of
stimulation in patients with various numbers of oocytes retrieved after stimulation with highly puriﬁed human menopausal gonadotropin
(hphMG) or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist protocol. Values are median (lines), 25th–75th
percentile (boxes), and 10th–90th percentile (whiskers). hphMG:%3 (n ¼ 47), 4–7 (n ¼ 124), 8–14 (n ¼ 145), 15–19 (n ¼ 38),R 20 (n ¼ 18);
recombinant FSH:%3 (n ¼ 25), 4–7 (n ¼ 112), 8–14 (n ¼ 147), 15–19 (n ¼ 55),R 20 (n ¼ 30).
Arce. AMH, oocytes, and cumulative live births. Fertil Steril 2013.
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONsigniﬁcantly higher ongoing pregnancy and live-birth rates
in the fresh cycle were observed for the hphMG-treated pa-
tients in the two highest quartiles compared with the two low-
est quartiles (35% and 34% vs. 23% and 23%, P¼ .007 and
P¼ .013, respectively).
Among the recombinant FSH-treated patients, there was
no statistically signiﬁcant increase in pregnancy or live-birth
rates in the fresh cycle in the two highest AMH quartiles com-
pared with the two lowest (29% and 27% vs. 24% and 24%,
P¼ .236 and P¼ .462, respectively) due to an apparent reduc-
tion in pregnancy and live-birth rates in the fresh cycle in the
highest quartile.
A total of 222 patients (107 for hphMG and 115 for re-
combinant FSH) underwent up to 6 cryopreserved replace-
ment cycles, for a total of 355 cycles and an average of 1.61648 0.9 in the hphMG group and 1.6  1.0 in the recombinant
FSH group. No pregnancies were achieved after the third
cryopreserved cycle. In the cryopreserved cycles, the ongoing
pregnancy and live-birth rates per started stimulation cycle
statistically signiﬁcantly increased (P< .022) across the
AMH quartiles, from 8% in the <25th percentile to 15% in
the >75th percentile (see Table 2), reﬂecting the statistically
signiﬁcant (P< .001) relationship between AMH and number
of cryopreserved blastocysts. Nevertheless, the ongoing preg-
nancy and live-birth rates per blastocyst transferred in cryo-
preserved cycles were not statistically signiﬁcantly (P¼ .195)
different between the AMH quartiles nor increased with the
AMH quartiles (30%, 18%, 30%, and 25% in quartiles 1, 2,
3, and 4, respectively; identical percentages for ongoing preg-
nancy and live-birth rates).VOL. 99 NO. 6 / MAY 2013
FIGURE 2
Receiver operating characteristic (ROC) curve analysis showing the predictive values of antim€ullerian (AMH), follicle-stimulating hormone (FSH),
inhibin B, and antral follicle count (AFC) at start of stimulation for estimation of poor ovarian response (%3 oocytes retrieved or cycle
cancellation due to poor response) and high response (R15 oocytes retrieved or cycle cancellation due to excessive response), respectively,
after controlled ovarian stimulation in patients treated with highly puriﬁed human menopausal gonadotropin (hphMG) or recombinant FSH in
a gonadotropin-releasing hormone (GnRH) antagonist protocol. The diagonal line is the reference line of no discrimination (area under the
curve ¼ 0.5).
Arce. AMH, oocytes, and cumulative live births. Fertil Steril 2013.
Fertility and Sterility®The cumulative (i.e., combined fresh and cryopreserved
cycles) rates of ongoing pregnancy (P< .001) and live-birth
(P< .001) were positively associated with the AMH concentra-
tion at the start of stimulation. In both treatment groups,
higher outcome rates were observed among patients with
AMH >50th percentile compared with the patients with
AMH%50th percentile. Respectively, the ongoing pregnancy
rates were for hphMG, 50% versus 31% (P< .001); and re-
combinant FSH, 46% versus 33% (P¼ .010). The live-birth
rates were for hphMG, 49% vs. 31% (P< .001); and recombi-
nant FSH, 43% vs. 33% (P¼ .030). Including age in the logistic
regression analyses showed that this potential confounding
variable had no statistically signiﬁcant impact on the preg-
nancy and live-birth rates, neither in fresh nor in cumulative
cycles (data not shown).
DISCUSSION
The results of this study showed that the AMH concentration
at start of stimulation is predictive of the ovarian response inVOL. 99 NO. 6 / MAY 2013good-prognosis patients undergoing COS in a GnRH antago-
nist cycle. This ﬁnding is in line with numerous previous
studies in patients following a long GnRH agonist protocol
(1–8). The correlation between AMH and the number of
oocytes retrieved was superior to those for other hormonal
markers of the ovarian reserve (i.e., FSH and inhibin B), as
previously shown elsewhere for the long GnRH agonist
protocol (2). The ROC analyses indicated that the basal
serum AMH concentration was a better predictor of poor as
well as high ovarian response than FSH or inhibin B in
cycles controlled with a GnRH antagonist. This observation
was independent of the type of gonadotropin preparation
used for stimulation.
It should be noted that the relative differences in AMH
values between patients with few and many oocytes retrieved
were larger than the interindividual differences of the other
markers of ovarian reserve, including AFC. In our study,
the measurements of AMH and AFC were performed on
the same day: the ﬁrst day of stimulation just before1649
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONgonadotropin exposure. Hence, the moderate correlation of
0.48 between AMH and AFC suggests either that these two
markers of ovarian reserve represent somewhat different fol-
licle cohorts or that there is an inﬂuence of the variability of
these assessments. The usefulness of AFC as a predictor of
ovarian response has primarily been established in single-
center investigations rather than inmulticenter studies, which
suggests sonographer-dependent variability. Although
single-center studies have indicated that early-follicular
phase AFC and AMH show similar correlations to the number
of oocytes retrieved (9, 10, 20), we found that AMH better
correlated with the ovarian response than AFC, reproducing
the ﬁndings of earlier multicenter trials (3, 15).
Our ﬁnding that patients with an AMH level below the
25th percentile had statistically signiﬁcantly fewer oocytes
retrieved after COS than the patients in the other AMH quar-
tiles emphasizes the current view that low oocyte yield is
mainly a sign of diminished ovarian reserve (9, 21, 22) and,
to a lesser extent, of gonadotropin underdosing. The
alternative explanation that follicles in these patients were
less sensitive to FSH was not supported by the evidence,
which showed that the duration of stimulation, and
therefore the FSH-mediated growth rate, was not longer in
the patients with low AMH values.
The potential disadvantages of assigning all patients to
a nonindividualized dose regimen for the ﬁrst 5 days, irre-
spective of a large interindividual variability of basal serum
AMH levels, were evident. This conventional approach
resulted in an initial inadequate follicular response in one-
fourth of the total study population, as measured by transva-
ginal ultrasound on stimulation day 6. Because the patients
with a ‘‘required’’ gonadotropin-dose increase on day 6
were distinguished by a lower basal AMH concentration com-
pared with the patients who had no need for a dose adjust-
ment during stimulation, it can be hypothesized that an
increase of their starting dose beyond 150 IU may have re-
sulted in a higher ovarian response for some of these patients
and, possibly, reduced cycle cancellation rates without an in-
creased risk of OHSS. However, a couple of studies in patients
deﬁned as low responders based on a low AMH or AFC before
starting the ﬁrst COS cycle did not report improvements in the
number of oocytes retrieved or the pregnancy rates by in-
creasing the starting gonadotropin doses (23, 24).
Prospective (25) and retrospective (26) studies have indi-
cated potential beneﬁts of using AMH to individualize treat-
ment strategies for COS. In the large prospective (but not
randomized) study by Nelson et al. (25), a reduction in the in-
cidence of underresponse and overresponse to stimulation
was observed when assigning patients with low or high
AMH levels to the GnRH antagonist protocol, with high and
low gonadotropin doses, respectively, while assigning the
patients with normal AMH levels to the long GnRH agonist
protocol. These ﬁndings were recently supported in a large
retrospective study by Yates et al. (26), who reported that em-
bryo transfer, pregnancy, and live-birth rates per cycle started
increased signiﬁcantly when using stratiﬁed COS protocols
that were tailored to individual AMH levels as compared
with conventional nonindividualized stimulation, although
the patients with very low AMH levels were excluded. Large1650prospective, randomized, controlled trials to evaluate the
potential clinical beneﬁts of individual treatment strategies
for patients undergoing their ﬁrst IVF/ICSI cycle are needed
before any ﬁrm conclusions can be drawn in relation to
AMH-based individual dosing algorithms.
Although the cutoff values of AMH for prediction of low
or high ovarian response were quite similar between the treat-
ment groups, there were some differences in the clinical re-
sponse in each AMH quartile depending on the type of
gonadotropin. Treatment with hphMG was associated with
a somewhat lower oocyte yield in patients with a medium
or high AMH value at start of stimulation compared with re-
combinant FSH treatment. Consequently, the occurrence of
a high ovarian response (R15 oocytes retrieved) and preven-
tive interventions or OHSS treatment among patients with
higher basal AMH values was more common in the recombi-
nant FSH group than in the hphMG group. Despite a larger
oocyte yield among the recombinant FSH-treated patients
with AMH above the 75th percentile, apparently lower ongo-
ing pregnancy and live-birth rates in the fresh cycle were ob-
served in the recombinant FSH group, which inﬂuenced the
cumulative ongoing pregnancy and live-birth rates in that
group.
Our study showed no statistically signiﬁcant differences
in the number of available blastocysts on day 5 between the
AMH quartiles when adjusting for the number of oocytes re-
trieved. This is in accordance with the poor predictive value
for AMH as a marker of qualitative aspects of the ovarian re-
serve when using a GnRH agonist protocol (3, 7, 13, 27, 28).
Although there was a statistically signiﬁcant association
between AMH and ongoing pregnancy in the fresh cycle in
our study, the ROC analyses showed that AMH was not an
absolute predictor of ongoing pregnancy in the fresh cycle,
which is in agreement with several large studies of patients
undergoing COS using a GnRH agonist protocol (1, 3, 21,
29). However, statistically signiﬁcantly higher cumulative
ongoing pregnancy and live-birth rates were observed with
increasing AMH levels. This documents the importance of
AMH in the cumulative outcome of a single stimulation cycle,
even when evaluating mainly patients who are considered to
have a good ovarian reserve. The logistic regression analysis
indicated that the statistically signiﬁcant positive association
between AMH and outcome rates was most likely mediated
through increased oocyte yields, and therefore more blasto-
cysts available for fresh and cryopreserved cycles, rather
than a direct association between AMH and oocyte/blastocyst
quality. This conclusion is further strengthened by the obser-
vation that no statistically signiﬁcant differences in preg-
nancy or live-birth rates per blastocyst transferred in
cryopreserved cycles were observed between the AMH quar-
tiles. Consequently, the analysis of combined fresh and cryo-
preserved cycles showed stronger associations between AMH
and outcome than the analysis of fresh cycles alone.
Our study has shown that AMH predicts the number of
oocytes retrieved in good-prognosis patients undergoing
COS in a GnRH antagonist cycle. We found that AMH is a bet-
ter predictor of poor and high ovarian response than basal
FSH, inhibin B, or AFC. The value of AMH as a predictor of
treatment outcome is clearly evident after combinedVOL. 99 NO. 6 / MAY 2013
TABLE 2
Variables obtained at baseline, stimulation day 6, and end of stimulation as well as outcome variables grouped by AMH quartiles at start of
stimulation.
Variable
AMH quartilesa
Q1:<25th (<13 pmol/L) Q2: 25th–50th (13–23 pmol/L)
All (n[ 185) hphMG (n[ 91) rFSH (n[ 94) All (n[ 189) hphMG (n[ 99) rFSH (n[ 90)
Start of stimulation
AMH (pmol/L) 7 (3, 10) 7 (3, 10) 6 (2, 10) 17 (15, 21) 18 (15, 21) 17 (15, 20)
Age (y) 32 (30, 33) 32 (30, 33) 32 (30, 33) 31 (29, 32) 31 (29, 33) 31 (29, 32)
Age range (y) 21–34 21–34 22–34 22–34 22–34 23–34
BMI (kg/m2) 21.9 (20.3, 23.9) 21.9 (20.3, 23.5) 21.9 (20.3, 24.2) 21.8 (20.3, 23.5) 21.6 (20.4, 23.3) 22.0 (20.0, 23.8)
FSH (IU/L) 7.9 (6.7, 9.7) 7.9 (6.8, 9.9) 8.1 (6.5, 9.6) 7.2 (6.2, 8.2) 7.2 (6.1, 8.3) 7.2 (6.4, 8.2)
Inhibin B (ng/L) 76 (55, 100) 72 (55, 100) 79 (55, 103) 81 (61, 97) 81 (59, 98) 82 (65, 97)
AFC (n) 11 (10, 14) 11 (10, 14) 12 (10, 14) 14 (12, 17) 14 (12, 17) 14 (11, 17)
Stimulation day 6
FolliclesR10 mm (n) 5 (3, 6) 5 (3, 7) 5 (3, 6) 7 (5, 9) 6 (4, 8) 7 (5, 9)
Estradiol (nmol/L) 2.1 (1.3, 2.9) 2.3 (1.4, 2.9) 1.8 (1.2, 2.7) 2.5 (1.7, 3.3) 2.3 (1.8, 3.2) 2.5 (1.7, 3.4)
Gonadotropin dose adjustment
Decrease, n (%) 1 (1%) 1 (1%) 0 (0) 0 (0) 0 (0) 0 (0)
No change, n (%) 101 (56%) 47 (52%) 54 (59%) 139 (75%) 72 (74%) 67 (76%)
Increase, n (%) 79 (44%) 42 (47%) 37 (41%) 46 (25%) 25 (26%) 21 (24%)
Missing, n (%) 4 (2%) 1 (1%) 3 (3%) 4 (2%) 2 (2%) 2 (2%)
Gonadotropin dose (IU) 150 (150, 225) 150 (150, 225) 150 (150, 225) 150 (150, 150) 150 (150, 225) 150 (150, 150)
End of stimulation
Treatment days (n) 8 (7, 9) 8 (7, 9) 8.5 (7, 9) 9 (8, 9) 9 (8, 9) 8 (8, 9)
Total gonadotropin dose (IU) 1,350 (1,125, 1,650) 1,350 (1,200, 1,650) 1,350 (1,050, 16,509) 1,350 (1,200, 1,500) 1,350 (1,200, 1,575) 1,350 (1,200, 1,500)
Cycle cancellation, n (%) 12 (6%) 5 (5%) 7 (7%) 2 (1%) 2 (2%) 0 (0)
Poor response, n (%) 12 (6%) 5 (5%) 7 (7%) 2 (1%) 2 (2%) 0 (0)
Excessive response, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
FolliclesR10 mm (n) 8 (6, 10) 8 (5, 11) 8 (6, 10) 12 (9, 14) 11 (9, 14) 12 (9, 15)
Progesterone (nmol/L) 2.4 (1.7, 3.1) 2.4 (1.6, 3.1) 2.4 (1.7, 3.1) 2.5 (1.9, 3.2) 2.4 (1.9, 3.0) 2.7 (2.0, 3.6)
Progesterone >4 nmol/L, n (%) 20 (12%) 11 (13%) 9 (11%) 20 (11%) 8 (8%) 12 (14%)
Early OHSS (moderate/severe), n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Interventions due to excessive ovarian
responseb, n (%)
4 (2%) 1 (1%) 3 (3%) 4 (2%) 2 (2%) 2 (2%)
Outcome
Oocyte retrieval, n (%) 170 (92%) 85 (93%) 85 (90%) 184 (97%) 96 (97%) 88 (98%)
Oocytes retrieved (n) 5 (4, 7) 5 (3, 8) 6 (4, 7) 8 (6, 11) 7 (5, 10) 9 (7, 12)
Patients with oocytes retrieved
according to categories, n (%)
%3 oocytes 40 (24%) 24 (28%) 16 (19%) 10 (5%) 9 (9%) 1 (1%)
4–7 88 (52%) 38 (45%) 50 (59%) 76 (41%) 45 (47%) 31 (35%)
8–14 39 (23%) 20 (24%) 19 (22%) 84 (46%) 38 (40%) 46 (52%)
15–19 3 (2%) 3 (4%) 0 (0) 10 (5%) 2 (2%) 8 (9%)
R20 0 (0) 0 (0) 0 (0) 4 (2%) 2 (2%) 2 (2%)
Blastocysts available, n (%) 131 (71%) 62 (68%) 69 (73%) 167 (88%) 86 (87%) 81 (90%)
Blastocysts (n) 1 (0, 2) 1 (0, 2) 1 (0, 2) 2 (1, 3) 1 (1, 3) 2 (1, 4)
Blastocysts (n)/oocytes
retrieved (n), (%)
25% (13%, 43%) 25% (0, 40%) 25% (14%, 43%) 25% (13%, 41%) 26% (16%, 41%) 23% (11%, 41%)
Blastocyst transfer, n (%) 132 (71%) 62 (68%) 70c (74%) 168 (89%) 87c (88%) 81 (90%)
Blastocyst transfer for patients with
oocytes retrieved, n (%)
132 (79%) 62 (73%) 70c (84%) 168 (91%) 87c (91%) 81 (92%)
Blastocysts cryopreserved, n (%) 79 (43%) 39 (43%) 40 (43%) 99 (52%) 49 (49%) 50 (56%)
Blastocysts cryopreserved (n) 0 (0, 1) 0 (0, 1) 0 (0, 1) 1 (0, 3) 0 (0, 2) 1 (0, 3)
Blastocysts cryopreserved (n)/oocytes
retrieved (n), (%)
0 (0, 25%) 0 (0, 20%) 0 (0, 25%) 10% (0, 30%) 8% (0, 29%) 11% (0, 32%)
Fresh cycle
Ongoing pregnancy, n (%) 45 (24%) 22 (24%) 23 (24%) 42 (22%) 21 (21%) 21 (23%)
Live birth, n (%) 45 (24%) 22 (24%) 23 (24%) 42 (22%) 21 (21%) 21 (23%)
Cryopreserved cycles
Ongoing pregnancy, n (%) 14 (8%) 7 (8%) 7 (7%) 17 (9%) 8 (8%) 9 (10%)
Live birth, n (%) 14 (8%) 7 (8%) 7 (7%) 17 (9%) 8 (8%) 9 (10%)
Fresh þ cryopreserved cycles
Ongoing pregnancy, n (%) 59 (32%) 29 (32%) 30 (32%) 59 (31%) 29 (29%) 30 (33%)
Live birth, n (%) 59 (32%) 29 (32%) 30 (32%) 59 (31%) 29 (29%) 30 (33%)
Note: Continuous data are presented as median (interquartile range), and categorical data as frequency and percentage. AFC ¼ antral follicle count; AMH ¼ antim€ullerian hormone; BMI ¼ body
mass index; rFSH ¼ recombinant follicle-stimulating hormone; hphMG ¼ highly puriﬁed human menopausal gonadotropin; OHSS ¼ ovarian hyperstimulation syndrome.
a The AMH quartiles were deﬁned for the total study population.
b Cycle cancellation, paracentesis, or albumin administration.
c One patient with transfer of a nonblastocyst is included.
d Kruskall-Wallis test.
e Chi-square test.
f Fisher's exact test.
g Logistic regression.
h Linear regression.
i Poisson regression.
j Binominal regression.
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AMH quartilesa
P valueQ3:>50th–75th (>23–37 pmol/L) Q4:>75th (>37 pmol/L)
All (n[ 187) hphMG (n[ 97) rFSH (n[ 90) All (n[ 188) hphMG (n[ 87) rFSH (n[ 101)
AMH
quartile
AMH
overall
AMH overall/
treatment
30 (26, 33) 30 (27, 33) 30 (25, 33) 49 (43, 62) 51 (44, 62) 48 (43, 59) < .001d
31 (29, 33) 31 (29, 33) 30.5 (29, 32) 30 (28, 32) 30 (28, 33) 30 (28, 31) < .001d < .001h < .026h
21–34 21–34 23–34 22–34 22–34 23–34
22.0 (20.4, 24.0) 22.3 (21.1, 24.1) 21.5 (20.3, 23.8) 21.8 (20.5, 23.5) 22.1 (21.0, 23.9) 21.6 (20.1, 23.0) .744d .530h .192h
6.9 (6.0, 7.9) 6.9 (6.0, 7.8) 6.8 (6.0, 7.9) 6.5 (5.7, 7.6) 6.7 (5.6, 7.7) 6.4 (5.7, 7.5) < .001d < .001h .303h
85 (66, 106) 88 (70, 108) 78 (63, 101) 91 (69, 116) 90 (73, 115) 93 (66, 118) < .001d < .001h .244h
16 (12, 19) 16 (12, 19) 15 (12, 19) 18 (15, 22) 18 (15, 22) 18 (15, 22) < .001d < .001i .706i
8 (5, 10) 7 (5, 9) 9 (5, 12) 9 (6, 12) 8 (4, 10) 10 (7, 14) < .001d < .001i < .001i
2.9 (2.0, 3.8) 2.9 (1.9, 3.8) 2.9 (2.2, 3.9) 3.1 (1.9, 4.8) 2.4 (1.5, 4.2) 3.4 (2.4, 5.1) < .001d < .001h .005h
< .001e < .001g .018g
3 (2%) 1 (1%) 2 (2%) 8 (4%) 2 (2%) 6 (6%)
140 (75%) 68 (71%) 72 (80%) 137 (73%) 61 (70%) 76 (75%)
43 (23%) 27 (28%) 16 (18%) 43 (23%) 24 (28%) 19 (19%)
1 (1%) 1 (1%) 0 (0) 0 (0) 0 (0) 0 (0)
150 (150, 150) 150 (150, 225) 150 (150, 150) 150 (150, 150) 150 (150, 225) 150 (150, 150) < .001d < .001h .013h
9 (8, 9) 9 (8, 10) 8 (8, 9) 9 (8, 10) 9 (8, 10) 9 (8, 9) .002d .017i .015i
1,350 (1,200, 1,500) 1,350 (1,200, 1,575) 1,350 (1,200, 1,425) 1,350 (1,200, 1,500) 1,350 (1,200, 1,650) 1,350 (1,200, 1,500) .845d .244h .001h
2 (2%) 1 (1%) 1 (1%) 1 (1%) 0 (0) 1 (1%) < .001f
1 (1%) 1 (1%) 0 (0) 0 (0) 0 (0) 0 (0)
1 (1%) 0 (0) 1 (1%) 1 (1%) 0 (0) 1 (1%)
14 (11, 18) 14 (11, 17) 15 (12, 18) 18 (14, 21) 17 (13, 20) 19 (15, 21) < .001d < .001i .007i
2.7 (2.1, 3.4) 2.7 (2.1, 3.7) 2.6 (2.0, 3.2) 2.9 (2.1, 3.8) 2.8 (2.1, 3.9) 3.0 (2.1, 3.8) < .001d < .001h .441h
22 (12%) 17 (18%) 5 (6%) 44 (24%) 21 (24%) 23 (23%)
4 (2%) 3 (3%) 1 (1%) 8 (4%) 3 (3%) 5 (5%)
8 (4%) 1 (1%) 7 (8%) 19 (10%) 7 (8%) 12 (12%) .002e .002g .437g
185 (99%) 96 (99%) 89 (99%) 185 (98%) 85 (98%) 100 (99%) .001e < .001g .960g
10 (7, 14) 10 (7, 13) 12 (8, 15) 12 (9, 17) 12 (8, 15) 14 (10, 19) < .001d < .001i < .001i
< .001e < .001g < .001g
2 (1%) 1 (1%) 1 (1%) 5 (3%) 5 (6%) 0 (0)
46 (25%) 28 (29%) 18 (20%) 26 (14%) 13 (15%) 13 (13%)
91 (49%) 47 (49%) 44 (49%) 78 (42%) 40 (47%) 38 (38%)
32 (17%) 15 (16%) 17 (19%) 48 (26%) 18 (21%) 30 (30%)
14 (8%) 5 (5%) 9 (10%) 28 (15%) 9 (11%) 19 (19%)
164 (88%) 86 (89%) 78 (87%) 162 (86%) 73 (84%) 89 (88%) < .001e .008g .376g
3 (1, 5) 2 (1, 4) 3 (1, 5) 3 (1, 6) 3 (1, 6) 3 (1, 6) < .001d < .001i .063i
25% (11%, 43%) 24% (11%, 43%) 27% (11%, 43%) 25% (11%, 43%) 27% (12%, 43%) 22% (10%, 40%) .937d .346j .705j
162 (87%) 84 (87%) 78c (87%) 159 (85%) 72 (83%) 87 (86%) < .001e < .001g .264g
162 (88%) 84 (88%) 78c (88%) 159 (86%) 72 (85%) 87 (87%) < .007e < .032g .164g
120 (64%) 58 (60%) 62 (69%) 122 (65%) 59 (68%) 63 (62%) < .001e < .001g .505g
2 (0, 4) 1 (0, 4) 2 (0, 4) 2 (0, 5) 2 (0, 5) 2 (0, 5) < .001d < .001i .072i
14% (0, 33%) 12% (0, 32%) 18% (0, 33%) 15% (0, 33%) 17% (0, 35%) 12% (0, 30%) .004d .075j .751j
64 (34%) 34 (35%) 30 (33%) 57 (30%) 31 (36%) 26 (26%) .037e .038g .519g
62 (33%) 33 (34%) 29 (32%) 53 (28%) 30 (34%) 23 (23%) .088e .085g .413g
29 (16%) 14 (14%) 15 (17%) 29 (15%) 13 (15%) 16 (16%) .022e .004g .566g
29 (16%) 14 (14%) 15 (17%) 29 (15%) 13 (15%) 16 (16%)
93 (50%) 48 (49%) 45 (50%) 86 (46%) 44 (51%) 42 (42%) < .001e < .001g .843g
91 (49%) 47 (48%) 44 (49%) 82 (44%) 43 (49%) 39 (39%) < .001e < .001g .724g
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Fertility and Sterility®evaluation of the fresh and cryopreserved cycles. A high AMH
level is associated with increased cumulative ongoing preg-
nancy and live-birth rates, which is in line with its ability
to predict higher yields of oocytes and blastocyst availability.
Our results also suggest that further examination of differen-
tial approaches or dosing regimens to ovarian stimulation de-
termined by an individual's AMH level is warranted.
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SUPPLEMENTAL TABLE 1
Patient demographics, baseline characteristics, and serum endocrine concentrations at start of stimulation.
Variable All (n[ 749) hphMG (n[ 374) rFSH (n[ 375)
Baseline
Age (y) 31 (29, 33) 31 (29, 33) 31 (29, 32)
Weight (kg) 60 (56, 64) 60 (56, 65) 60 (55, 64)
BMI (kg/m2) 21.9 (20.4, 23.7) 22.1 (20.7, 23.7) 21.7 (20.2, 23.8)
Cycle length (d) 28 (28, 30) 28 (28, 30) 28 (28, 30)
Duration of infertility (y) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 2.5 (1.9, 4.0)
Primary reason for infertility
Mild male factor, n (%) 457 (61%) 232 (62%) 225 (60%)
Unexplained, n (%) 292 (39%) 142 (38%) 150 (40%)
Day 1 of stimulation (cycle d 2–3)
AMH (pmol/L) 23 (13, 37) 23 (13, 36) 24 (13, 39)
21–29 y 28 (17, 44); n ¼ 239 28 (17, 43); n ¼ 111 27 (17, 44); n ¼ 128
30–34 y 21 (11, 34); n ¼ 510 21 (11, 33); n ¼ 263 20 (10, 36); n ¼ 247
FSH (IU/L) 7.0 (6.1, 8.2) 7.1 (6.2, 8.2) 6.9 (6.0, 8.2)
Inhibin B (ng/L) 84 (64, 105) 85 (65, 105) 83 (59, 105)
LH (IU/L) 5.9 (4.6, 7.6) 5.9 (4.6, 7.8) 5.9 (4.6, 7.6)
Estradiol (nmol/L) 0.16 (0.13, 0.21) 0.16 (0.13, 0.21) 0.16 (0.13, 0.20)
Progesterone (nmol/L) 2.0 (1.5, 2.7) 2.0 (1.5, 2.6) 2.0 (1.5, 2.7)
AFC (n) 15 (12, 18) 15 (12, 18) 14 (11, 18)
Note: Continuous data are presented as median (interquartile range) and categorical data as frequency and percentage. AFC ¼ antral follicle count; AMH ¼ antim€ullerian hormone; BMI ¼ body
mass index; FSH¼ follicle-stimulating hormone; rFSH¼ recombinant follicle-stimulating hormone; LH¼ luteinizing hormone; hphMG¼ highly puriﬁed humanmenopausal gonadotropin; OHSS¼
ovarian hyperstimulation syndrome.
Arce. AMH, oocytes, and cumulative live births. Fertil Steril 2013.
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